EU Accelerated Assessment Tracker
Pharming’s leniolisib has lost its accelerated assessment status at the European Medicines Agency while Krystal Biotech’s beremagene geperpavec will be fast-tracked once a filing has been made.
You may also be interested in...
Givinostat, Italfarmaco’s investigational treatment for Duchenne muscular dystrophy, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
Securing a place on the European Medicines Agency’s priority medicines scheme is not easy, but some companies have managed to make the grade more than once.
EU marketing authorization applications have been submitted for a number of new drugs, including Eli Lilly’s donanemab, Italfarmaco's givinostat and Arcturus Therapeutics/CSL’s ARCT-154.